1. Alemany A, Millat-Martinez P, Corbacho-Monné M, Suñer C, Galvan-Casas C, Carrera C et al (2023) Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine 10(57):101898
2. Ali S, Uddin SM, Shalim E, Sayeed MA, Anjum F, Saleem F et al (2021) Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial. EClinicalMedicine 4(36):100926
3. Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E et al (2021) Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy 13(5):397–407
4. Al-Riyami AZ, Burnouf T, Wood EM, Devine DV, Oreh A, Apelseth TO et al (2022) International society of blood transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. Vox Sang 117(6):822–830
5. Ambrose N, Amin A, Anderson B, Barrera-Oro J, Bertagnolli M, Campion F et al (2023) Neutralizing monoclonal antibody use and COVID-19 infection outcomes. JAMA Netw Open 6(4):e239694